2022/02/18
Recently, Beilu Pharma received the “Approval Notice for Supplementary Drug Application” for two specifications of Iopamidol Injection issued by the NMPA (Notice No.: 2022B00641, 2022B00642). Following Iohexol Injection, Iodixanol Injection and Gadopentetate Dimeglumine Injection, it is the company’s fourth Contrast Agent product passed the quality and efficacy consistency evaluation of generic drugs.